| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
|
|
04-28-2010, 10:58 PM
|
#1 | |||
|
||||
|
Senior Member
|
They did this back in late February, when they also found out that the Food and Drug Administration (FDA) had decided to give the drug "priority review" status.
We should hear something by the end of June. It will be interesting to see how many of us will jump on the "oral drug bandwagon" and how many will stay with our current drugs. Of course, our neurologists also have a role in our medications. 
__________________
LADY May happiness be at your door. May it knock early, stay late, and leave the gift of good health behind. "Life is what it is". We can only focus on controlling those things we can control, we must let go of the things we can't. |
|||
|
 Reply With Quote
|
| Reply |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| FTY720/Fingolimod | Multiple Sclerosis | |||
| Novel mechanism of FTY720 identified | Multiple Sclerosis | |||
| Fingolimod/FTY720 Research from ECTRIMS | Multiple Sclerosis | |||
Novartis had changed the name of Fingolimod to Gilenia (aka FTY720).
Hybrid Mode
